Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Echo IQ Limited has appointed veteran healthcare executive Matthew Dodds as Chief Financial Officer, and earlier this month Mayo Clinic announced a research collaboration assessing Echo IQ’s AI platform for cardiac risk stratification in oncology patients, with study results expected in the first half of 2027. Together, the leadership change and Mayo Clinic collaboration highlight Echo IQ’s efforts to deepen US healthcare relationships while exploring broader clinical uses for its EchoSolv...
Matthew Dodds appointed Chief Financial Officer, bringing over 30 years of healthcare, medical technology, capital markets, corporate development and investor relations experience Dr. Vinod Thourani appointed Clinical Advisor, adding one of the world's leading structural heart and valve disease specialists to Echo IQ's growing network of key opinion leaders SYDNEY, June 24, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) ("Echo IQ" or "the Company") today an
Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer therapyResearch collaboration with Mayo Clinic to evaluate EIQ’s AI platform for cardiac risk stratification in oncology patientsStudy to assess the ability of Echo IQ's AI technology to evaluate cardiac risk in patients undergoing cancer therapy using routinely acquired echocardiographic dataTargets the rapidly emerging cardio-oncology sector, a growing market driven b
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.